Block Admission

ABZENA PLC

("Abzena", the "Company" or the "Group")

Block Admission

7 July 2015

Cambridge, UK - Abzena plc (AIM: ABZA), a life sciences company providing services and technologies that enable the development of better biopharmaceutical products, today announces a

block admission has been made of 1,779,000 ordinary shares of £0.002 pence each (the "New Ordinary Shares") to trading on AIM (the "Block Admission"). The New Ordinary Shares are expected to be admitted to trading on AIM on 13 July 2015 ("Admission").

The New Ordinary Shares will be issued from time to time pursuant to the exercise of options under the Group's 2013 Share Incentive Plan and will, when issued rank pari passu with the existing ordinary shares of the Company.

Following Admission, the Company will continue to have 97,468,858 ordinary shares of £0.002 pence each in issue, each with voting rights. No shares are held in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For more information, please contact:

John Burt (Chief Executive Officer)

Julian Smith (Chief Financial Officer)

Abzena plc

Tel: +44 (0)1223 903498

Email: john.burt@abzena.com or julian.smith@abzena.com

Christopher Golden and Ivonne Cantu

Cenkos Securities (Nominated Adviser and Broker)

Tel: +44 (0)20 7397 8900

Mark Swallow, Chris Gardner or Pip Batty

Citigate Dewe Rogerson (Corporate and Financial PR)

Tel: +44 (0)20 7638 9571

Email: abzena@citigatedr.co.uk

About Abzena

Abzena provides proprietary technologies and complementary services to enable the development of better biopharmaceuticals. The Group comprises PolyTherics and Antitope which have established a broad suite of services and technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals.

The Group has built a global customer base over the past decade which includes the majority of the top 20 biopharmaceutical companies, many large and small biotech companies, and academic groups.

Abzena is quoted on the AIM segment of the London Stock Exchange under the symbol ABZA.

www.abzena.com